In lat­est set­back for sol­id tu­mor CAR-T, Celyad paus­es tri­al fol­low­ing two pa­tient deaths

Ef­forts to push CAR-T ther­a­py, so ef­fec­tive in many blood can­cers, in­to sol­id tu­mors took an­oth­er hit Mon­day, af­ter Celyad On­col­o­gy an­nounced that two pa­tients had died in a tri­al for its lead can­di­date for col­orec­tal can­cer.

Celyad said it had “vol­un­tar­i­ly” paused the tri­al as it in­ves­ti­gates the deaths, al­though such vol­un­tary ac­tions of­ten come im­me­di­ate­ly be­fore the FDA or EMA or­ders stud­ies halt­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER